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Around 75% of cancer survivors report symptoms of chemotherapy-induced cognitive impairment 
(CICI) lasting one month to 20 years. The underlying mechanisms remain largely unknown and the 
symptoms reported can be significant. Animal models are used to investigate CICI, however there is 
no gold standard model in terms of the time-point or chemotherapeutic agents investigated, which 
reflects the clinical scenario. This study investigated an acute time-point of 72 hours post-treatment 
of methotrexate (MTX) or 5-Fluorouracil (5-FU) in a rat model, as there is limited knowledge on 
early time course pathogenesis of CICI. 
 
METHODS 
Female Sprague Dawley rats received two injections of MTX (37.5mg/kg), 5-FU (75mg/kg) or saline 
intraperitoneally. Animals were assessed in the puzzle box and novel object recognition (NOR) to 
examine hippocampal and prefrontal cortex (PFC) functioning. Western blot analysis was conducted 
on PFC and hippocampal tissue to examine astrocytic activation through GFAP expression. 
 
RESULTS 
MTX treatment revealed impaired long-term memory in the puzzle box, however no significant 
differences were found in NOR. Both 5-FU and MTX increased GFAP expression in PFC 
significantly. Additionally, 5-FU increased hippocampal GFAP expression. This suggests impairment 
may occur in the hippocampus later on for MTX, or 5-FU has more extensive severity for damage. 
 
CONCLUSION 
These results demonstrate that MTX and 5-FU treatment produce an inflammatory response at 72 
hours post-treatment in the PFC and hippocampus, whereas cognition is partially affected. This could 
potentially provide insight as to when and how to inhibit CICI from occurring. 




Chemotherapy treatment is among the most common cancer treatment utilised today. Due to medical 
advances, chemotherapeutic agents have produced relative success shown through an increase in 
cancer survivor numbers1. However, with the use of such agents comes adverse side effects, including 
neurotoxicity, often resulting in deficits in attention, concentration, speed of information processing 
and decision making2. This is a condition termed chemotherapy-induced cognitive impairment (CICI) 
or ‘chemobrain.’ As many as 75% of patients report symptoms during treatment1, 3, 4, and 35% 
continue to report them post-treatment3. Studies suggest that these impairments can last between 6 
months5 to 20 years6 and varies in terms of severity and duration.  
The mechanisms driving CICI are largely unknown, however several mechanisms have been 
proposed. These include the ability of chemotherapeutic agents to alter the permeability of the blood 
brain barrier (BBB) and promotion of oxidative stress and neuroinflammation1. Neuroinflammatory 
mechanisms have recently been recognised as a key contributor driving CICI. The brain’s innate 
immune system can become activated due to inflammatory challenges, and cellular and molecular 
changes occur as a result, as shown in CICI studies7, 8. Astrocytes are key mediators in the immune 
response in the central nervous system (CNS)8. In terms of chemotherapy treatment, 
neuroinflammation may be an outcome of peripheral inflammatory signalling due to the effect on the 
tumour, such as gut-brain activation. Or it could be a direct consequence of the agents localising to 
CNS cells causing a cascade of neuroinflammatory events and neurotoxicity, resulting in cognitive 
decline9.  
Methotrexate (MTX) and 5-Fluorouracil (5-FU) are commonly used cytotoxic agents to treat 
patients with various forms of cancer, such as Non-Hodgkin’s lymphoma, acute lymphoblastic 
leukaemia10, breast and colorectal cancer11. Both agents have been implicated in many clinical and 
pre-clinical CICI studies, suggesting a possible negative effect on cognition1, 2, 12-16. MTX has been 
shown to impair performance on object recognition in rats, affecting hippocampal function15, whereas 
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5-FU has the ability to cross the BBB, impairing cognition and supressing hippocampal cell 
proliferation17.  
Several clinical studies have investigated CICI, examining dose amount, drug type, route of 
administration and administration either alone or in combination18. However, many confounding 
variables must be accounted for, such as cancer type, treatment regime, age and sex, which can all 
result in conflicting outcomes. Therefore, animal models are widely utilised, as they are more 
effective at controlling for these variables1. However, methodological differences exist across animal 
models and there is no ‘gold standard’ model. As a consequence, studies utilise different rodent 
strains, sex, chemotherapeutic agents, route of administration, dose frequency and behavioural tests1. 
A further challenge is the lack of simple behavioural tests of cognition available to assess more subtle 
cognitive changes, as might be expected in CICI. 
Previous animal studies investigating CICI have focused on both acute and chronic time points 
with MTX and/or 5-FU treatment with inconsistent results1. The time-point at which impairment 
occurs is largely unknown as the reported cognitive impairment and duration often vary. This is of 
particular importance as the duration and prevalence of CICI reported in humans also varies. 
Cognitive impairment has been identified in rodent studies investigating CICI with MTX and/or 5-
FU treatment at 1 to 3 days and 1 week to 5 weeks post treatment2, 13, 15, 16, 19, 20. Conversely, no 
significant impairment has been found at 3 days, 1 week and 3 weeks up to 15 weeks12, 13, 21.  A 
limited number of studies have explored an acute time-point of 72-hours while simultaneously 
investigating both behavioural and neuroimmune expression changes. This highlights the importance 
for a study like this one to continue to chart the time frame in which CICI may be occurring, and the 
possible underlying neuroimmune mechanisms.  
As such, the primary aim of this study was to elucidate both hippocampal and PFC focussed 
cognitive impairment at 72 hours post chemotherapy treatment, along with the related astrocytic 
activation for these regions. The second aim was to validate the puzzle box test in a CICI rat model. 
It was hypothesised that rats administered either MTX or 5-FU would show greater cognitive 
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impairment in behavioural tests compared to saline-treated controls. Additionally, an increase in 
astrocytic activation in the PFC and hippocampus would occur, as determined through glial fibrillary 
acidic protein (GFAP) expression.  
 
Ethics 
The University of Adelaide’s Animal Ethics Committee approved the animal housing and 
experimental procedures for this study (S-2019-019). It was conducted in accordance with the 
provisions of the Australian Code for the Care and Use of Animal for Scientific Purposes. The 
following study is reported in accordance with Animal Research: Reporting in vivo experiments: The 
ARRIVE guidelines22. 
 
Materials and Methods 
Animals and Experimental Design 
Female Sprague Dawley (Hsd: SD) rats (n=36) aged eight weeks, were purchased from a pathogen-
free, barrier-maintained animal facility (Laboratory Animal Services, University of Adelaide). The 
sample size per treatment group was calculated to achieve 80% power based on previous data. The 
number of animals required was derived using a standard deviation of 3.5s, with an effect size of 
0.74, providing a statistical power of 82.6%. Animals were group housed (six per cage) in open-top 
cages (415mm x 260mm x 145mm, Tecniplast, Exton, PA, USA) with clean bedding (1/4-inch Grit-
ology Enriched Corncob, Corn-cob-ology, NSW, Australia). A room temperature of 21-23oC and a 
standard 12-hour light/dark cycle with lights on at 7am and off at 7pm was maintained. Animals were 
acclimatised for five days prior to the commencement of the study. Animals were provided with a 
standard diet of chow (Teklad Irradiated Global SoyProtein-Free Extruded Rodent Diet 2920X, 
Envigo, Madison, WI) and acidified RO water ad libitum for the duration of the study. Animals were 
randomly assigned to three treatment groups (n=12), using an online random number generator 
(Randomness and Integrity Services Ltd, Dublin, Ireland).  
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Animals received an intraperitoneal injection of MTX (37.5mg/kg; Accord Healthcare Pty 
Ltd, Melbourne, Australia), 5-FU (75mg/kg; Hospira Australia Pty Ltd, Victoria, Australia) or Saline 
(0.9% Sodium Chloride Inj.B. Braun Australia Pty Ltd), once weekly for two consecutive weeks prior 
to behavioural testing on days -7 and 0 (Figure 1). These chemotherapeutic agents were chosen due 
to their clinical relevance23 and dosages selected based on previous findings showing cognitive 
impairment with minimal adverse systemic effects20, 24. During chemotherapy treatment, animals 
additionally received Nutrigel (High-energy dietary supplement, Troy Laboratories Pty Ltd, NSW, 
Australia) and DietGel®31M (ClearH20, Portland, USA) to enhance nutrient intake.  
Animals were monitored daily, and weight recorded using the disease activity index (DAI) 
clinical record sheet. Puzzle box testing was conducted on days 0 to 3 post treatment and NOR was 
conducted on day 2 following the puzzle box trials for that day. Behavioural testing was conducted 
during the light cycle in the animal facility in a separate room to their housing. Animals were 
humanely euthanised on day 3 after behavioural testing by CO2 asphyxiation (20% of chamber 
volume per minute by rising fill). Animals remained in the chamber until they were flaccid and no 
longer respiring, confirmed via eye blink response and pedal reflex tests. PFC and hippocampal tissue 
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Figure 1. Overview of experimental timeline. 
 
Behavioural Testing 
1. Puzzle Box 
The protocol for the puzzle box was adapted from previously published protocols by Abdallah et al., 
(2011) and Shepard et al., (2017), with slight modifications made to obstacles to suit a rat model25, 26. 
The apparatus consisted of a rectangular acrylic box with a removable barrier to create two areas: a 






Figure 2. Diagram of puzzle box. 
 
Open-Field Zone Goal Box 
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Animals were firstly habituated to the puzzle box before receiving their final treatment, during which 
the door was removed (H1) and unobstructed (H2) for five minutes per trial. The test trials 
commenced after animals received their final treatment. During these trials, animals were faced with 
three different obstacles blocking entrance to the door, which increased in complexity to remove. A 
total of three trials were conducted per obstacle to test executive function, short-term memory (STM) 
and long-term memory (LTM). The first trial tested executive function to determine whether the 
animal could develop strategies to move past the obstacle. The second tested STM by allowing a 15-
minute gap in-between the first two trials and the third was conducted the following day to test LTM. 
Testing order was randomly assigned using an online random number generator (Randomness and 
Integrity Services Ltd, Dublin, Ireland). 
On day 0 for T1 the door was unobstructed. The door was then obstructed with clean bedding 
for the following two trials, requiring animals to burrow through to the door (T2-T3). On day 1, 
animals underwent the same trial again (T4). Following this, the door was obstructed with a soft 
rectangular plug consisting of a medium density foam, requiring animals to pull it away (T5-T6). On 
day 2 animals firstly underwent T7 for the final soft plug trial. A hard, wooden plug was then placed 
through the door requiring animals to push or pull it (T8-T9). T10 was finally conducted on the 
























Table 1. Puzzle Box timeline with day, trial number and trial condition, indicating whether 
executive function, STM or LTM was tested. 
 
The trials were conducted under homogeneous light. They commenced once the animal was placed 
into the open-field zone at the furthest point away from the goal box, with its body parallel to the 
sidewalls and nose facing away from the barrier hole to prevent any bias. The apparatus and materials 
were cleaned using 70% ethanol between animals to reduce olfactory cues. Each trial was video 
recorded using a Panasonic video camera (HC-V180, Panasonic Corporation, Kadoma, Osaka, 
Japan) placed above the apparatus. Videos were later analysed blindly using CowLog (Research 
Center for Animal Welfare and Department of Agricultural Sciences, University of Helsinki, 
Finland), with the latency to move into the goal box recorded. On analysis, latency time commenced 
once all four paws were in contact with the floor, while completion of the trial occurred either when 
all four paws entered the goal box or after five minutes had elapsed, indicating a failure. 
 
 
Day Trial Number Trial Condition 
-1 
 
H1 No barrier 
H2 Barrier present, open 
entrance 
0 T1 Barrier present, open 
entrance 
T2 Burrowing (EXECUTIVE) 
T3 Burrowing (STM) 
1 T4 Burrowing (LTM) 
T5 Soft plug (EXECUTIVE) 
T6 Soft plug (STM) 
2 T7 Soft plug (LTM) 
T8 Hard plug (EXECUTIVE) 
T9 Hard plug (STM) 
3 T10 Hard plug (LTM) 
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2. Novel Object Recognition Test (NOR) 
NOR was conducted on day 2 following the puzzle box trials for that day. The test was performed 
using the protocol developed by Bevins and Besheer (2006)27. The basis for the test being that rodents 
have a natural preference to explore novel objects28. Animals were placed in an enclosed arena 
measuring 50cm x 50cm x 50cm under a brightly lit area. The test consisted of three phases; 
habituation, where no objects were present, a familiar (T1) and a novel (T2) trial, each conducted for 
five minutes with a one hour break in-between. Each object was different in colour and shape but was 
of similar mass. To prevent coercion to explore the objects, animals were placed against the centre of 
the wall facing to the side of the objects. Each animal was randomised both in terms of the familiar 
and novel objects assigned to them and  also the position (left or right) that the novel object was 
placed using an online random number generator (Randomness and Integrity Services Ltd, Dublin, 
Ireland).  
T1 was conducted with two identical objects affixed to middle of the arena slightly apart from 
each other. T2 was similar to T1, however one of the objects was replaced with an unfamiliar, novel 
object (Figure 3). The surface and objects were cleaned using 70% ethanol between animals to reduce 
olfactory cues. Each trial was video recorded using a Panasonic video camera placed above the arena, 
as previously described. Videos were later blindly analysed using ANY-maze (ANY-maze UK, IL, 
USA) and object interaction time was recorded. Animals were removed from analysis if they did not 
spend a minimum of ten seconds exploring the objects in T129. Object interaction time was scored 
based on the length of time spent investigating the objects when in direct contact. The degree of object 
recognition was determined using a preference index score, where the time spent investigating the 
novel object was divided by the sum exploration of the novel and familiar objects30. 
 









Figure 3. NOR set-up; T1 with two identical objects and T2 with one familiar object from T1 and a 
novel object. 
 
Disease Activity Index (DAI) 
DAI was recorded at four time points; baseline (prior to receiving final treatment), 24, 48 and 72-
hours post treatment. DAI was measured based on overall appearance, weight loss, stool consistency 











* Overall appearance based on pre-determined criteria; dull/ruffled coat, poor posture/hunched, 
pale/sunken eyes, behaviour change, dehydration, squealing when handled and reluctant to move. 
Table 2. Scoring criteria for DAI. 













Mild diarrhoea 2 




No visible blood 0 
Blood spots 1 
Blood in faeces 2 
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Western Blot  
Fresh, snap frozen PFC and hippocampal tissue were homogenised in standard RIPA buffer, 
centrifuged and the supernatant collected. A BCA assay kit (Pierce BCA, Thermo Fisher Scientific 
Inc, #23227) was used for protein estimation. Gel electrophoresis was performed using Bolt 4-12% 
Bis-Tris Plus gels (Thermo Fisher Scientific Inc) at 150V for 1.5 hours. Gels were transferred to a 
PVDF membrane using the iBlot 2 Dry Blotting System (Thermo Fisher Scientific Inc). Membranes 
were stained in ATX Ponceau S staining solution for five minutes and washed with tris buffered saline 
plus tween (TBST) until the Ponceau was removed. 5% skim milk solution (5g skim milk powder, 
100ml TBST) was used to block the membranes at room temperature for two hours. Following this, 
membranes were washed another three times and incubated for two hours in 2% skim milk solution 
(1g skim milk powder, 100ml TBST) overnight on a rotating device with primary antibodies (GFAP; 
#ab7620, Abcam, Cambridge, UK) and housekeeper protein (GAPDH; #ab8245 Abcam, Cambridge, 
UK). Membranes were washed a further three times and incubated with secondary antibodies (LICOR 
800CW (green) donkey/anti-rabbit 1:10,000; LICOR 800W (green) donkey/anti-mouse, 1:10,000) 
for two hours at room temperature in 2% skim milk solution on a rotating device covered with 
aluminium foil. Western blots were imaged using the Odyssey Infrared Imaging System (model 9120; 
software version 3.0.21) (LI-COR, Inc). Analysis of band signals were performed using ImageJ 
version 1.49 (Wayne Rashband, National Institutes of Health, USA). 
 
Data Analysis 
Data were checked for normality and heterogeneity utilising the Shapiro Wilk test and analysed 
parametrically or non-parametrically as appropriate. Data were considered significant if p<0.05. 
Statistical analyses were performed using MegaStat Excel Add-In (Version 10.3 Release 3.1.6, 
McGraw-Hill Higher Education, New York, NY, USA) and SPSS (SPSS Inc., Chicago, IL, USA). A 
statistician was consulted for analysis of puzzle box data. Data are presented as mean ± standard error 
of the mean (SEM), unless otherwise stated.  





1. Puzzle Box 
A two-way repeated measures ANOVA was conducted across ten time points between three treatment 
groups for both group and within-subject factors. This test was chosen as previous literature analysed 
their puzzle box data using this method25, 26, 31. Significance was found between treatment groups, 
(F(2,33)=4.302, p=0.022). A Tukey HSD post-hoc test with a Bonferroni correction for multiple 
comparisons found time-point differences between MTX and saline treatment, specifically at T7, 
(p=0.026) and T10, (p=0.035) (Figure 4 and 5). A number of animals did not complete several trials 












Figure 4. Puzzle box latency to complete task (s).  
* indicates significance found at T7 (p=0.026) and T10 (p=0.035) between MTX and saline 
treatment. Data presented as mean ± SEM. 
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Figure 5. Puzzle box latency to complete task (s); executive function (A), STM (B) and LTM (C) 
testing trials. * p<0.05 at T7 and T10 for LTM testing between MTX and saline treatment. Data 
presented as mean ± SEM. 
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2. Novel Object Recognition (NOR) 
A total of six animals were excluded from analysis, as they did not meet the required ten second 
minimum spent exploring the objects in T1 (5-FU=2, MTX=2 and Saline=2). A one-way ANOVA 











Figure 6. NOR preference index scores %. n=10 per treatment group. No significance found, 
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Disease Activity Index (DAI) 
A Friedman’s test was conducted on DAI scores within groups, across time at baseline, 24, 48 and 
72 hours. Scores increased significantly over time (X2(3)=15.160, P=0.002). Post-hoc analysis using 
the Wilcoxon Signed Rank test found significance between MTX and saline treated animals across 
time between baseline and 72 hours, and 48 and 72 hours, (p=0.014 and p=0.016), respectively. A 
Kruskal Wallis H test was conducted to analyse between-group differences at individual time-points. 
Significance was found between treatment groups, (H(2)=12.757, p=0.002). Post-hoc analysis using 
a Mann-Whitney U test found significance at 72-hours between MTX and 5-FU (p=0.13) and MTX 









Figure 7. DAI scores at four time points; baseline, 24, 48 and 72 hours.  
* p<0.05 across time between baseline and 72 hours, and 48 and 72 hours between MTX and 













































A one-way ANOVA was performed on PFC and hippocampal relative density. Significance was 
found for both the PFC, (F(2,15)=5.351, p=0.018), and hippocampus, (F(2,15=12.861, p=0.001). A 
Tukey HSD post-hoc test found significant differences between 5-FU and saline (p=0.027) and MTX 
and saline (p=0.037) in the PFC. Significance was also found in the hippocampus between 5-FU and 














Figure 8. Analysis of GFAP relative density within PFC (A) and hippocampal (B) tissue. n=6 per 
treatment group. * p<0.05 between 5-FU and saline and MTX and saline for the PFC, and 5-FU 



























































CICI is a debilitating condition greatly impacting a person’s life by affecting their ability to complete 
everyday tasks3, 9, 32. The aim of this study was to investigate the effects of MTX and 5-FU treatment 
on cognition at an acute time-point of 72 hours in a rat model, as displayed through performance in 
behavioural tests. Furthermore, the study aimed to provide evidence of a neuroimmune response 
occurring in the hippocampus and PFC at this time point. An additional aim was to validate the puzzle 
box test in a CICI rat model. The results from this study demonstrate that minimal cognitive 
impairment occurred at 72 hours post chemotherapy treatment. As shown through behavioural testing, 
impairment was only evident in the hard plug LTM testing trials, but not in others. However, glial 
activation in the PFC and hippocampus was found to be significantly different in both treatment 
groups.  
The puzzle box was utilised as a novel PFC and hippocampal based task in a rat model of 
CICI. Differences observed occurred in trials testing for LTM for the hard plug obstacle, indicating 
that LTM may be affected in MTX treated animals at 72 hours following chemotherapy treatment. 
However, no differences were found in other trials that tested executive function and STM. Memory 
impairment is a common symptom reported in human cancer survivors. A longitudinal study of breast 
cancer survivors found that 61% reported memory impairment33. Similarly, animal studies have 
observed impairment in multiple memory tests in rodents, particularly with MTX and 5-FU 
treatment14, 16. However, it is important to be cautious about drawing conclusions based on results 
from this study alone. In this study, several animals did not complete trials in the allocated time, as 
they were not able to move past the obstacle into the goal box. This was particularly evident in the 
last few trials that utilised the hard plug obstacle. This could indicate that animals found the trials too 
difficult, or they had reduced motivation. However, as little significance was found between control 
and treatment groups in behaviour, it is unlikely that motivation towards completing the trials was 
the main reason as to why several animals did not enter the goal box. DAI scores indicated that 
animals were experiencing toxic effects from the chemotherapy treatment and therefore they may 
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have felt too unwell to complete the task.  Previous studies utilising the puzzle box to assess cognitive 
function have done so in mice. This is the first CICI study to utilise it in rats, however further 
validation is required to ensure the obstacles chosen are correct. The puzzle box has been investigated 
in one CICI study, where mice treated with the chemotherapeutic agent cisplatin, took significantly 
more time to enter the goal box during the more difficult trials, indicating treated mice were 
cognitively impaired34. The test has also been utilised in other rodent studies, through investigating 
the efficacy of environmental enrichment31, as well as diseases such as schizophrenia, where all mice 
showed altered executive functions25, and dementia, where STM was found to be impaired in mice35. 
However, motivation is less likely to be impaired in these models compared to CICI models. This 
indicates that there is potential for the puzzle box test to be investigated further in other diseases such 
as CICI, as it can detect subtle cognitive impairment and requires no prior training. 
NOR is a well validated behavioural test of cognition, however there is great variability in 
results seen in CICI research. This study did not observe any differences, which is similar to other 
studies where mice treated with 5-FU performed on par with controls after one week12. Furthermore, 
MTX treated rats showed no difference in novel object exploration compared to controls after three 
and seven days13. However, a study found cognitive impairment was occurring in rats administered 
with MTX after three weeks as they failed to distinguish the novel object15. This suggests that 
cognitive impairment could be occurring at a later time-point. NOR only tests the hippocampus for 
recognition memory, whereas CICI may be primarily affecting the PFC at this time-point36. NOR 
may also not be detecting more subtle cognitive changes. This could be due to only the hippocampus 
being tested, or the impairment induced being less severe at this time. Therefore, the use of more 
sensitive tests to detect subtle cognitive changes may be required. CICI does not only affect one brain 
region, it can impair cognition in the prefrontal, frontal, temporal and parietal regions1. Multiple 
behavioural tests that focus on different brain regions may be needed to detect the full extent of 
impairment and highlight why the puzzle box assessing both PFC and hippocampal function could 
be useful. 
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DAI scores increased over the four time points in chemotherapy treated animals. Taken with 
the behavioural findings, this suggests that gastrointestinal toxic effects from the chemotherapeutic 
agents are more severe than neurotoxic effects at 72 hours following chemotherapy treatment. MTX 
and 5-FU elicit mucositis rapidly37-39 within 72 hours following chemotherapy treatment in rats37-39. 
Due to these rapid toxic effects, it is challenging to determine whether the behavioural tests are a true 
representation of the cognitive impairment incurred, or are instead a result of illness and reduced 
motivation to perform the tests40. It is proposed that chemotherapy exposure influences the gut-brain 
axis via different mechanisms which include the fact that gastrointestinal peripheral effects precede 
CNS effects41. Therefore, 72 hours may be too early to see cognitive changes occur41 if toxic effects 
are occurring in the gut prior to the CNS.  
Astrocytic activation was analysed through GFAP expression. Increased astrocytic activation 
was found in the PFC and hippocampus in MTX and 5-FU treated animals. However, whilst 5-FU 
treated animals were affected in both the PFC and hippocampus, MTX treated animals were only 
affected in the PFC. This suggests that the PFC may be impacted first by chemotherapy, with 
hippocampal damage occurring later, or that 5-FU has an increased neurotoxic effect compared to 
MTX. Both MTX and 5-FU and  are antimetabolites, however 5-FU is able to cross the BBB14 and 
may therefore cause potential damage to specific brain regions sooner, whereas MTX may have a 
more indirect effect through being unable to cross the BBB42. This could explain why it could 
potentially take longer to affect these brain regions. Similarly, a study examining mice administered 
with chemotherapeutic agents; docetaxel, adriamycin and cyclophosphamide, saw an increase in 
GFAP levels in the PFC, but not the hippocampus43. Astrocytes are involved in the maintenance and 
permeability of the BBB, forming a selective barrier for entry of immune cells into the CNS8. The 
release of inflammatory mediators such as cytokines and astrocytes is necessary to perform normal 
physiological functions, however when inflammation becomes excessive, this can lead to alterations 
in the structure and function of the CNS8. Future studies could investigate inflammatory cytokine 
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expression at this time-point in these regions, along with markers for microglial activation, such as 
IBA1, to produce a more comprehensive picture of the neuroimmune response. 
 The puzzle box is a relatively new behavioural assay, and to the best of our knowledge is the 
first study to investigate in rat models of CICI. It has potential to provide an easy method to assess 
PFC and hippocampal functioning, however it has not been well validated thus far, therefore making 
it a limitation to the study. The challenge was finding an appropriate behavioural test for a 72-hour 
time-point. An alternative test such as the five-choice serial reaction time test, is a PFC based task 
that allows for the investigation of cognitive impairment beyond the hippocampus. However, this 
would not have been possible to conduct as animals are required to undergo extensive prior training. 
Future studies could therefore look to develop an improved protocol for the puzzle box, such as 
validating the obstacles.  
In conclusion, this study aimed to examine both hippocampal and PFC cognitive impairment 
at 72 hours post chemotherapy treatment, along with the related astrocytic activation for these regions. 
The second aim was to validate the puzzle box test in a CICI rat model. The results demonstrate that 
no significant impairment was observed in cognition through behavioural testing. Additionally, glial 
activation occurs in the PFC and hippocampus in rats treated with MTX and 5-FU at 72-hours 
following chemotherapy treatment. Therefore, no explicit link between the response and cognitive 
changes has been identified. However, this could be a precursor to the cognitive changes that may be 
occurring. Future studies are therefore vital to chart the time course of behavioural and neuroimmune 
reactivity marker expression changes over multiple time-points, in an effort to target and inhibit CICI 
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